EUCTR2012-000699-40-IT进行中（未招募）不适用
A Study of BR55 in Contrast Enhanced Ultrasound Imaging in Patients with Ovarian and Breast Cancer. - Exploratory of BR55 in Ovarian and Breast Cancer
BRACCO IMAGING0 个研究点开始时间: 2012年5月28日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •For all Participants: 1. Signed Informed Consent obtained. For ovarian Patients: 1. Post menopausal female; 2.No menstrual period for at least one year; 3. Age =18 years; 4. Established or suspected ovarian cancer diagnosis based on the following criteria: ovarian mass not greater than 10 cm in size / with suspected malignant solid component confirmed by diagnostic imaging / with or without extra-ovarian cancer spread including ascites and-or omental caking and-or peritoneal nodules/Scheduled to undergo ovarian surgery for primary cancer or ovarian mass within 30 days after enrollment. For breast Patients: 1. Female; 2. Age = 18 years; 3. Established or suspected breast cancer diagnosis based on diagnostic imaging (mammography, ultrasound, and/or MRI); 4. Scheduled to undergo primary breast cancer surgery or large core biopsy of the breast within 30 days after enrollment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 55
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 55
排除标准
- •Exclude a patient from this study if the subject does not fulfill the inclusion criteria, or if any of the following conditions are observed: Has a body weight =95 kg Has undergone prior systemic therapy for ovarian or breast cancer Has history of concurrent malignancy Has history of any clinically unstable cardiac condition including class III/IV congestive heart failure Has known right to left cardiac shunt, bidirectional or transient Has had any severe cardiac rhythm disorders within 7 days prior to enrolment Is known to suffer from stable angina pectoris and/or has suspected or proven coronary disease Has severe pulmonary hypertension (pulmonary artery pressure >90mmHg) or uncontrolled systemic hypertension and/or respiratory distress syndrome Has open and/or non-healing wounds in the chest, abdomen and pelvis Has other systemic vascular abnormalities associated with neovascularization, such as macular degeneration, that in the opinion of the investigator could significantly affect the ability to evaluate the effects of BR55. Is unable to comply with study protocol requirements for any reason. Is participating in a clinical trial or has participated in another trial with an investigational compound within the past 30 days prior to enrolment Has previously been enrolled in and completed this study Has any known allergy to one or more ingredients of the Investigational Product or to any other contrast media It is determined by the Investigator that the patient is clinically unsuitable for the study Ovarian Patients Additional exclusion criteria: Major surgery, including laparoscopic surgery, within 3 months prior to enrolment Breast Patients: Additional exclusion criteria: Pregnancy or breastfeeding. Exclude the possibility of pregnancy: o By testing on site at the institution (serum ßHCG) within 24 hours prior to the start of the IMP administration o By surgical history (e.g. tubal ligation or hysterectomy) Post menopausal within a minimum one year without menses History of significant acute or chronic breast abnormalities (e.g. infection or trauma) in the breast of interest. History of minor (e.g., fine-needle aspiration, needle core biopsy, vacuum-assisted core biopsy, cyst aspiration, or other similar procedures) or major (e.g., mastectomy, breast-conserving surgery, implants, open surgical biopsy, breast radiotherapy, or other similar procedures) procedures in the breast of interest.
研究者
相似试验
已完成
不适用
Contrast enhansed ultrasound in evalution of in-stent prtrusion after carotid stenting.Stroke,Carotid stenosisJPRN-UMIN000024727Department of Stroke Medicine,Kawasaki Medical School20
进行中（未招募）
2 期
BR55 in Characterization of Ovarian LesionsOvarian CancerNCT03493464Bracco Diagnostics, Inc14
进行中（未招募）
不适用
Contrast enhanced ultrasonography effectiveness in early evaluating of the response to the Sunitinib in the patients with advanced GIST. A pilot study - NDGastrointestinal stromal tumor (GIST)MedDRA version: 9.1Level: LLTClassification code 10061174Term: Gastrointestinal neoplasmEUCTR2007-001928-12-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
招募中
不适用
Quantification of Contrast Enhanced Ultrasound (CEUS) in the detection of Prostate cancer.Prostate adenocarcinoma10038364Prostate cancerNL-OMON36092Academisch Medisch Centrum560
招募中
不适用
Comparison of Contrast-Enhanced Ultrasonography with Contrast-Enhanced CT for Diagnosis of Liver Metastases from Colorectal tumorcolorectal tumorJPRN-UMIN000034484Department of Endoscopy, Nagoya university hospital280